ArticleEuropean journal of clinical pharmacology2026
Unveiling the sumatriptan dose-relief relationship.
Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis article aims to correlate the pharmacokinetic parameters of sumatriptan to the percentage of patients experiencing relief after two hours.
methodsUsing data from the literature, a two-compartment pharmacokinetic model is developed to compute the concentration of sumatriptan in the brain across various routes of administration and doses. This concentration is then correlated to its clinical effect.
resultsThe maximum concentration of sumatriptan in the brain correlates linearly with the percentage of patients experiencing pain relief after two hours. Based on the evolution over time of the brain concentration, the action time can also be predicted for different route-dose combinations.
conclusionThe present correlation provides a relationship between the dose of sumatriptan and its effect for multiple routes of administration. The approach developed in this work could be adapted to other molecules to explore their dose-response relationships.
Indexed as
Identifiers
42458128What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.